These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28005456)

  • 1. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab).
    Hong J; Lee Y; Lee C; Eo S; Kim S; Lee N; Park J; Park S; Seo D; Jeong M; Lee Y; Yeon S; Bou-Assaf G; Sosic Z; Zhang W; Jaquez O
    MAbs; 2017; 9(2):364-382. PubMed ID: 28005456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the physicochemical and biological stability of reconstituted and diluted SB2 (infliximab).
    Kim J; Chung J; Park S; Jung S; Kang D
    Eur J Hosp Pharm; 2018 May; 25(3):157-164. PubMed ID: 29732144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.
    Schreiber S; Yamamoto K; Muniz R; Iwura T
    Pharmacol Res Perspect; 2020 Jun; 8(3):e00604. PubMed ID: 32500668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®.
    Xu Y; Xie L; Zhang E; Gao W; Wang L; Cao Y; Xie MH; Jiang W; Liu S
    MAbs; 2019 Apr; 11(3):606-620. PubMed ID: 30794092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab.
    Liu Y; Xie J; Li Z; Mei X; Cao D; Li S; Engle L; Liu S; Ebbers HC; Liu C
    BioDrugs; 2024 Jul; 38(4):571-588. PubMed ID: 38890199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques.
    Fang J; Doneanu C; Alley WR; Yu YQ; Beck A; Chen W
    MAbs; 2016; 8(6):1021-34. PubMed ID: 27260215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system.
    An Q; Zheng Y; Zhao Y; Liu T; Guo H; Zhang D; Qian W; Wang H; Guo Y; Hou S; Li J
    Drug Des Devel Ther; 2019; 13():791-805. PubMed ID: 30880912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab.
    Velayudhan J; Chen YF; Rohrbach A; Pastula C; Maher G; Thomas H; Brown R; Born TL
    BioDrugs; 2016 Aug; 30(4):339-51. PubMed ID: 27422671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference Product.
    Seo N; Guan X; Wang T; Chung HSH; Wikström M; Padaki R; Kalenian K; Kuhns S; Matthies K; Crouse-Zeineddini J; Wong HY; Ng M; Foltz IN; Cao S; Liu J
    Ophthalmol Ther; 2024 May; 13(5):1303-1320. PubMed ID: 38507189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical Characterization for Similarity Assessment Between an Aflibercept Biosimilar SB15 and Reference Product (Eylea
    Lee H; Huh J; Kim D; Lee S; Lee J; Lee J; Kim BC; Song J
    Ophthalmol Ther; 2024 Aug; 13(8):2209-2225. PubMed ID: 38878130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab.
    Liu J; Eris T; Li C; Cao S; Kuhns S
    BioDrugs; 2016 Aug; 30(4):321-38. PubMed ID: 27461107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality by Design-Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®.
    Zhang E; Xie L; Qin P; Lu L; Xu Y; Gao W; Wang L; Xie MH; Jiang W; Liu S
    AAPS J; 2020 May; 22(3):69. PubMed ID: 32385732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®.
    Lee C; Jeong M; Lee JJ; Seo S; Cho SC; Zhang W; Jaquez O
    MAbs; 2017; 9(6):968-977. PubMed ID: 28640663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
    Radin M; Sciascia S; Roccatello D; Cuadrado MJ
    BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar.
    Kim S; Song J; Park S; Ham S; Paek K; Kang M; Chae Y; Seo H; Kim HC; Flores M
    MAbs; 2017; 9(4):704-714. PubMed ID: 28296619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars in inflammatory bowel disease.
    Gargallo CJ; Lué A; Gomollón F
    Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
    D'Haens G; Reinisch W; Colombel JF; Panes J; Ghosh S; Prantera C; Lindgren S; Hommes DW; Huang Z; Boice J; Huyck S; Cornillie F;
    J Crohns Colitis; 2017 Jun; 11(6):680-689. PubMed ID: 28025307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.
    Chang S; Hanauer S
    Curr Treat Options Gastroenterol; 2017 Mar; 15(1):53-70. PubMed ID: 28164249
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.